Lumida
/CRVL
⌘K
CorVel Corp

CorVel Corp

CRVL
$61.70USD↓-0.88%-0.55 today

MARKET CAP

3.1B

P/E (TTM)

31.2x

FWD P/E

—

DAY RANGE

$61 – $64

52W RANGE

$45
$99

AI Summary

Stalk
StalkMedium

CRVL remains in a Stage 2 advancing phase backed by a confirmed Momentum Breakout and a clean series of higher highs and higher lows above rising EMAs. However, price is extended into overbought territory, reducing immediate execution favorability. A deferred entry on a pullback into the rising 9EMA/21EMA zone or the prior breakout support offers a higher-probability continuation setup while maintaining the medium-term bullish exposure.

  • ↑Q1 revenue $249M (+7% YoY); FY 2026 revenue $959M (+7%)
  • ↑New bookings surged 56%, highlighting strong Network Solutions demand
  • ↓Elevated leverage risk could strain finances if rates rise
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

CorVel Corporation (NASDAQ: CRVL) is a leading provider in the healthcare technology sector, specializing in integrated solutions for claims management, payment accuracy, and cost containment. With a strong emphasis on leveraging technology and analytics, CorVel operates primarily in the managed workers' compensation industry. The company is adapting to increasing claims complexity in a changing labor market while focusing on improving clinical and financial outcomes for its healthcare partners.

Bull says

  • ↑Q1 revenue $249M (+7% YoY); FY 2026 revenue $959M (+7%)
  • ↑New bookings surged 56%, highlighting strong Network Solutions demand
  • ↑Repurchased 872K shares for $56M, reflecting $233M cash reserve
  • ↑Investing in AI and automation to boost claims accuracy and throughput
  • ↑Debt-free balance sheet with $66M free cash flow and 15% operating margin
  • ↑High earnings yield, positive analyst revisions, and low volatility risk

Bear says

  • ↓Elevated leverage risk could strain finances if rates rise
  • ↓High short interest reflects broad investor skepticism on growth
  • ↓Operating margin at 15% faces pressure from rising admin costs
  • ↓Revenue concentrated among few large payers risks contract disruptions
  • ↓Intense competition and workforce shortages may erode future market share
  • ↓No dividend yield and small size limit appeal to income investors

Investment themes with CRVL

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 05-21-2026bullish

Transcript signals

Bull points

  • revenues for the December quarter were $202 million, 13% over the $179 million of revenue for the December 2022 quarter.
  • Earnings per share for the quarter were $0.99, increasing 3% from the $0.96 per share in the same quarter of the prior year.
  • The revenue for patient management, including third-party administration, TPA services, and traditional case management for the December quarter was $132 million, an annual increase of 11%.

Bear points

  • The quarter's results were adversely impacted by elevated costs for our self-insurance healthcare, as well as, in the commercial health sector, volume-based price adjustments and continued tuning of the DRG review process.
  • During the quarter, the increase in generic drug costs was higher than usual, which resulted in the pharmacy program's gross margin experiencing a slight decline.
  • Liability claim costs are also experiencing steady growth due to the cost of labor and materials for property damage repairs and jury verdicts on bodily injury claims.
Read full transcript analysis ›